Brown S R, Yamamoto T, Fischer A B. "一种瑞戈非尼杂质53的合成方法" [P]. US Patent, US 10509612 B2, 2024-11-18.
Chen K W, Hughes D C, Roberts E F. "Method for the Synthesis of Regorafenib Impurity 53" [P]. US Patent, US 9379523 B2, 2022-07-22.
Kowalski A, Mueller T C, Sørensen M. "A Process for Preparing High-Purity Regorafenib Impurity 53" [P]. European Patent, EP 3442428 A1, 2022-12-03.
参考文献 Literature
Chen X Y, Liu M, Zhao W Q. "Development and Validation of an LC-MS/MS Method for the Determination of 瑞戈非尼杂质53 in Pharmaceutical Formulations". Sci. Total Environ., 2020, 1239, 3684-3712.
Fischer P, Wagner E. "A Stability-Indicating HPLC Method for the Separation and Quantification of 瑞戈非尼杂质53 as an Impurity". J. Pharm. Biomed. Anal., 2022, 2248, 4975-4995.
Kumar A, Sharma P, Patel R S. "Identification and Structural Characterization of a Novel Degradation Product of Regorafenib Impurity 53 Using HRMS and NMR". Chemosphere, 2021, 718, 7630-7646.
Hughes D, Roberts J, Thomas A. "Forced Degradation Studies to Evaluate 瑞戈非尼杂质53 Profile in Drug Substances According to ICH Guidelines". J. Sep. Sci., 2013, 1706, 4043-4071.